HIPEC has made continuous breakthroughs in theoretical research and technology, and has become an effective auxiliary means for the treatment of PC at present, which has been widely concerned by foreign scholars for a long time. At the 2014 International PC Conference in Amsterdam, the Netherlands, CRS combined with HIPEC treatment strategy was used as the standard treatment for appendix mucinous carcinoma, colorectal cancer peritoneal metastases, and malignant mesothelioma, and as the recommended treatment for ovarian cancer and gastric cancer peritoneal metastases[27]。 2018 New England Journal of Medicine report[3]After the first multicenter randomized controlled clinical trial of HIPEC in the treatment of advanced ovarian cancer, the 2018 FIGO Cancer Report included HIPEC in the guidelines for the diagnosis and treatment of ovarian cancer, and the first edition of NCCN in 2019 also included HIPEC in the guidelines for the treatment of ovarian cancer. The American Association Against Cancer also uses HIPEC as a recommended treatment for patients with peritoneal metastases of gastric cancer.